+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07686445

Evaluating Safety, Tolerability, and Antitumor Activity of AN4035 Alone or with EGFR Inhibitor in Advanced Solid Tumors with RAS Mutations and High CEACAM5

Led by Adlai Nortye Biopharma Co., Ltd. · Updated on 2026-10-16

228

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AN4035, a new drug designed to target advanced or metastatic solid tumors with RAS mutations and high CEACAM5 protein levels. This first-in-human Phase 1 study aims to test the safety, tolerability, and how the body processes AN4035, both alone and combined with cetuximab, in people whose cancer has progressed after standard treatments or who have refused standard therapies. The study also seeks to identify the best doses for future research and assess if AN4035 can slow or shrink tumors. Participants will receive AN4035 through intravenous infusion every two weeks, either alone or combined with cetuximab, a commercially available EGFR inhibitor. The study has two parts Part 1 involves gradually increasing AN4035 doses to find the highest safe dose and recommended dose for expansion, including monotherapy and combination therapy arms. Part 2 involves treating additional participants with the chosen doses to further evaluate safety and anti-tumor effects. Participants may continue treatment until cancer worsens, side effects are unacceptable, they choose to stop, or their doctor advises stopping. During the study, participants will have regular clinic visits for physical exams, blood tests to monitor drug levels and safety, scans to check tumor response, and health assessments. After treatment ends, follow-up visits will monitor health and disease status for up to 6 months or longer. Researchers will measure dose-limiting toxicities within 28 days, pharmacokinetics at multiple time points after dosing, and tumor responses every 8 weeks, focusing on safety, how the drug moves through the body, and preliminary anti-cancer activity.

CONDITIONS

Brief Title

A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

Research Team

A

Adlai Study Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here